We are a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders in metabolically challenged and in obese individuals. Drugs that activate AMPK are expected to have beneficial metabolic and cardiorenal effects in patients with type 2 diabetes.
Betagenon is financed by private Investors:
Fort Knox AB, www.fort-knox.se
The foundation Stiftelsen J.C. Kempes Minne, www.kempe.com